Velarion · Company Intelligence
Compensation Brief
Fiscal year 2026 · Filings through 2026-09-11

Mesa Laboratories (MLAB)

Former CEO Gary Owens was paid $6,643,208 in fiscal year 2026, ↑ up 0.7% from fiscal year 2025, the 37th percentile of its disclosed peer group (SEC filing 0000724004-26-000071 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$6,643,208 ↑
Gary Owens total, FY2026
37th
CEO pay percentile vs peers
79:1
CEO-to-median pay ratio
96.93%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

MLAB's next annual pay disclosure, estimated August 2, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2026

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Gary Owens$808,846$0$4,700,017$0$1,120,000$0$14,345$6,643,208
Former CEO and President
John Sakys498,38501,550,1500408,750014,2582,471,543
VP and Chief Financial Officer
Brian Archbold436,96201,400,0800331,250014,2262,182,518
SVP of Operations and Continuous Improvement

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2026 totalFY2025 totalFY2024 totalΔ FY2025→2026
Gary Owens$6,643,208$6,599,891$5,435,566↑ +43,317
John Sakys2,471,5432,424,1101,943,292↑ +47,433
Brian Archbold2,182,5182,134,5561,622,620↑ +47,962

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Mesa Laboratories's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper MLAB reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against MLAB
15 companies name MLAB as a compensation peer

The list of companies that name MLAB as a peer is temporarily unavailable — recheck shortly.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2026 total
Jennifer AlltoftIndependent Director$260,000
John SullivanChair of the Board$295,000
Mark CaponeIndependent Director$260,000
Shannon HallIndependent Director$250,000
Shiraz LadiwalaLead Independent Director$260,000
Siddhartha KadiaDirector—
Tony TripenyIndependent Director$260,000
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2026 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Tony TripenyDirector2026-08-13A900$114$102,321CommonForm 4 ↗
Siddhartha KadiaPresident and CEO2026-08-13A7,093113800,090Common, indirectForm 4 ↗
John SullivanDirector2026-08-13D7,093113800,090CommonForm 4 ↗
Shiraz LadiwalaDirector2026-08-15A3,81000CommonForm 4 ↗
John SullivanDirector2026-08-15D2,78400Derivative, Class A CommonForm 4 ↗
John SullivanDirector2026-08-15A2,78400CommonForm 4 ↗
Jennifer AlltoftDirector2026-08-15D2,78400Derivative, Class A CommonForm 4 ↗
Jennifer AlltoftDirector2026-08-15A2,78400CommonForm 4 ↗
Mark CaponeDirector2026-08-15A2,78400CommonForm 4 ↗
Tony TripenyDirector2026-08-15A2,78400CommonForm 4 ↗
Shannon HallDirector2026-08-15A2,78400CommonForm 4 ↗
Shiraz LadiwalaDirector2026-08-15D3,81000Derivative, Class A CommonForm 4 ↗
Mark CaponeDirector2026-08-15D2,78400Derivative, Class A CommonForm 4 ↗
Shannon HallDirector2026-08-15D2,78400Derivative, Class A CommonForm 4 ↗
Tony TripenyDirector2026-08-15D2,78400Derivative, Class A CommonForm 4 ↗
Dividend-equivalent accruals2026-09-09—5,322——3 insiders, 3 accrual rows
Shiraz LadiwalaDirector2026-09-09A2,51000Derivative, Class A CommonForm 4 ↗
Mark CaponeDirector2026-09-09A2,42300Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 20 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Tony TripenyDirector2026-08-13A900$114$102,321CommonForm 4 ↗
Siddhartha KadiaPresident and CEO2026-08-13A7,093113800,090Common, indirectForm 4 ↗
John SullivanDirector2026-08-13D7,093113800,090CommonForm 4 ↗
Shiraz LadiwalaDirector2026-08-15A3,81000CommonForm 4 ↗
John SullivanDirector2026-08-15D2,78400Derivative, Class A CommonForm 4 ↗
John SullivanDirector2026-08-15A2,78400CommonForm 4 ↗
Jennifer AlltoftDirector2026-08-15D2,78400Derivative, Class A CommonForm 4 ↗
Jennifer AlltoftDirector2026-08-15A2,78400CommonForm 4 ↗
Mark CaponeDirector2026-08-15A2,78400CommonForm 4 ↗
Tony TripenyDirector2026-08-15A2,78400CommonForm 4 ↗
Shannon HallDirector2026-08-15A2,78400CommonForm 4 ↗
Shiraz LadiwalaDirector2026-08-15D3,81000Derivative, Class A CommonForm 4 ↗
Mark CaponeDirector2026-08-15D2,78400Derivative, Class A CommonForm 4 ↗
Shannon HallDirector2026-08-15D2,78400Derivative, Class A CommonForm 4 ↗
Tony TripenyDirector2026-08-15D2,78400Derivative, Class A CommonForm 4 ↗
Tony TripenyDirector2026-09-09A1,77400Derivative, Class A CommonForm 4 ↗
Shiraz LadiwalaDirector2026-09-09A2,51000Derivative, Class A CommonForm 4 ↗
Mark CaponeDirector2026-09-09A2,42300Derivative, Class A CommonForm 4 ↗
Shannon HallDirector2026-09-09A1,77400Derivative, Class A CommonForm 4 ↗
John SullivanDirector2026-09-09A1,77400Derivative, Class A CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2026

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
John SakysPSU2025-06-153,8937,785—15,570$775,075
Gary OwensPSU2025-06-1511,80223,604—47,2082,350,014
Gary OwensRSU2025-06-15——24,659—2,350,003
Brian ArchboldRSU2025-06-15——7,346—700,074
John SakysRSU2025-06-15——8,133—775,075
Brian ArchboldPSU2025-06-153,5167,031—14,062700,006
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
John Sakys$775,075$775,075$050.0%
Gary Owens2,350,0032,350,014050.0%
Brian Archbold700,074700,006050.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2026

ExecutiveAwardShares unvestedExercise priceMarket value unvested
John SakysRSU2,281—$201,721
Gary OwensPSU9,621—850,689
John SakysRSU16,448—1,454,332
Gary OwensPSU25,608—2,264,259
Gary OwensRSU16,900—1,494,298
John SakysPSU3,138—277,462
John SakysPSU3,893—344,175
Brian ArchboldRSU844—74,626
Brian ArchboldRSU7,346—649,533
Gary OwensRSU11,559—1,022,047
Gary OwensPSU11,802—1,043,533
Gary OwensOption5,905131.67—
John SakysOption1,854131.67—
Brian ArchboldOption1,511131.67—
John SakysPSU8,352—738,484
Brian ArchboldPSU7,516—664,565
Brian ArchboldRSU4,960—438,563
Gary OwensRSU24,659—2,180,349
Gary OwensRSU7,280—643,680
John SakysRSU5,511—487,283
Brian ArchboldPSU3,516—310,885
Gary OwensRSU3,300—291,786
Brian ArchboldPSU2,824—249,698
Brian ArchboldRSU1,859—164,373
John SakysRSU1,036—91,603
05

Incentive-plan design — the Compensation Discussion & Analysis

The Compensation Committee oversees the executive compensation program for our NEOs. The program is designed to attract, retain, and motivate exceptional talent in a highly competitive market environment, while aligning executive team incentives with Mesa's long-term value creation for shareholders.

CEO STI target (% of salary)110%
CEO LTI target (% of salary)—
Independent consultantFrederic W. Cook & Co, Inc.
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-09-084,317,389136,78280,32696.93%Passed
20252025-08-224,476,544275,297134,65991.61%Passed
20242024-08-304,581,083226,77333,03094.63%Passed
20242024-08-304,581,083226,77333,03094.63%Passed
20232023-08-254,414,163188,692151,16892.85%Passed
20222022-08-261,039,4453,046,595296,88123.72%Failed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-09-0896.93%a
20252025-08-2291.61%b
20242024-08-3094.63%c

a. Voting standard not stated in the filing.

b. Approved under the standard stated in the filing — “An abstention will count as present for the purpose of determining the presence of a quorum but will have the effect of a vote against the proposal.”.

c. Approved under the standard stated in the filing — “An abstention will count as present for the purposes of determining the presence of a quorum but will have the effect of a vote against the proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)79 : 1
CEO total compensation$6,643,208
Median employee compensation$83,861
08

Director compensation — fiscal year 2026

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
John SullivanNot independent · Board Chair$105,000$190,000$0—$0$295,000
Jennifer AlltoftIndependent · Audit · Nominating and Governance (Chair)70,000190,0000—0260,000
Tony TripenyIndependent · Audit (Chair) · Compensation70,000190,0000—0260,000
Mark CaponeIndependent · Audit · Compensation (Chair)70,000190,0000—0260,000
Shiraz LadiwalaIndependent · Lead Independent Director · Nominating and Governance—260,0000—0260,000
Shannon HallIndependent · Compensation · Nominating and Governance60,000190,0000—0250,000
Siddhartha KadiaEmployee director · Partial-year service · Newly elected000—00
09

Board fee structure and ownership guideline

Annual cash retainer$60,000
Annual equity retainer$190,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)10,000 / 10,000 / 10,000
Stock ownership guideline3x annual retainer
09b

Total cost of the board

ComponentFY2026
Cash retainers and fees$375,000
Equity awards (grant-date value)$1,210,000
All other compensation$0
Total cost of the board$1,585,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2026

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Mesa Laboratories names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Mesa Laboratories.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Haemonetics Corporation2026Christopher Simon$1,100,008$7,561,987$1,504,968$1,834,250$12,044,701
2Sotera Health, LLC2025Michael Petras1,130,6998,022,40001,484,89010,656,063
3Azenta, Inc.2025John Marotta900,0008,386,29701,063,65610,371,414
4Maravai LifeSciences Holdings, Inc.2025Bernd Brust388,8637,660,0001,460,000425,34310,129,708
5AtriCure, Inc.2025Michael Carrel828,4397,203,47801,171,7039,217,620
6Neogenomics, Inc.2025Tony Zook601,5393,999,9973,998,235513,4009,127,092
7Adaptive Biotechnologies Corporation2025Chad Robins698,2587,675,1000703,3809,081,690
8Standard BioTools, Inc.2025Michael Egholm680,2565,337,8831,671,3631,120,0008,823,502
9Neogen Corporation2026Mike Nassif630,7693,250,0003,250,0001,000,0008,693,916
10Veracyte, Inc.2025Marc Stapley700,0005,890,8770826,0007,421,877
11BioLife Solutions, Inc.2024Roderick de Greef744,4505,571,8740655,1167,046,205
12Artivion, Inc.2025J. Patrick Mackin835,1455,006,9900991,3686,883,108
13Mesa Laboratories2026Gary Owens808,8464,700,01701,120,0006,643,208
14Quanterix Corporation2025Masoud Toloue670,9501,170,0002,729,998674,1725,250,745
15Cytek Biosciences, Inc.2025Wenbin Jiang620,0002,000,0002,000,000485,2115,120,061
16Pacific Biosciences of California, Inc.2025Christian Henry748,2501,151,0131,696,278714,3054,309,846
17LeMaitre Vascular, Inc.2025George LeMaitre806,3471,050,0001,050,000680,0153,780,990
18Inogen, Inc.2025Kevin R.M. Smith711,0771,874,550002,613,804
19Cryoport, Inc.2025Jerrell Shelton967,845192,300306,869908,5102,375,524
20Codexis, Inc.2025Alison Moore524,732255,9941,065,223463,1252,323,279

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Mesa Laboratories125%PSU 50 · RSU 50NoFrederic W. Cook & Co, Inc.
Adaptive Biotechnologies Corporationnot disclosedRSU 50 · PSU 50not disclosedSemler Brossy Consulting Group, LLC
Artivion, Inc.118.7%PSU 50 · RSU 50NoWillis Towers Watson
AtriCure, Inc.141%PSU 70 · RSU 30NoKorn Ferry
Azenta, Inc.not disclosedPSU 50 · RSU 50Yes — Relative TSR (rTSR)Pearl Meyer
BioLife Solutions, Inc.88%RSU 50 · Market-based RSU 50Yes — Total Shareholder Return (TSR)Frederic W. Cook & Co, Inc.
Codexis, Inc.95%not disclosednot disclosedPearl Meyer
Cryoport, Inc.92.2%not disclosednot disclosedFrederic W. Cook & Co., Inc.
Cytek Biosciences, Inc.78.4%RSU 50 · Options 50not disclosedMeridian Compensation Partners, LLC
Haemonetics Corporation133.4%PSU 60 · RSU 20 · Options 20Yes — Relative Total Shareholder Return (rTSR)Pearl Meyer & Partners, LLC
Inogen, Inc.60%RSU 50 · PRSU 50NoAon
LeMaitre Vascular, Inc.not disclosedOption 50 · RSU 25 · PSU 25Nonot disclosed
Maravai LifeSciences Holdings, Inc.not disclosednot disclosedNoMeridian Compensation Partners, LLC
Neogen Corporationnot disclosedPSU 50 · Option 50not disclosedFarient Advisors, LLC
Neogenomics, Inc.60%RSU 50 · Options 50not disclosedWTW
Pacific Biosciences of California, Inc.95%not disclosednot disclosedAon Human Capital Solutions
Quanterix Corporation95%Options 70 · RSU 30not disclosedPayGov
Sotera Health, LLC103%PSU 40 · RSU 40 · Other 20NoExequity, LLP
Standard BioTools, Inc.160%not disclosednot disclosedPearl Meyer
Veracyte, Inc.118%PSU 50 · RSU 50NoAon

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Mesa Laboratories in fiscal 2026?
As disclosed, Gary Owens (Former CEO and President) was the highest-paid executive at Mesa Laboratories in fiscal 2026, with total compensation of $6,643,208.
How does Mesa Laboratories's chief executive pay compare to its disclosed peer group?
As disclosed, Gary Owens's total compensation ranked at the 37th percentile of Mesa Laboratories's disclosed peer group.
What is Mesa Laboratories's CEO-to-median employee pay ratio?
As disclosed, Mesa Laboratories's CEO-to-median employee pay ratio was 79:1.
How did shareholders vote on Mesa Laboratories's executive compensation?
As disclosed, 96.93% of shareholders supported Mesa Laboratories's executive compensation in the latest say-on-pay vote.
How much does Mesa Laboratories spend in total on board compensation for fiscal 2026?
As disclosed, Mesa Laboratories reported total board compensation of $1,585,000 for fiscal 2026.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Gary OwensDEF 14A2026-07-220000724004-26-000071Section “Summary Compensation Table”. As printed: 6,643,208. Filing ↗machine: r3 · c24 · span 580946–580955
2Section 01, John SakysDEF 14A2026-07-220000724004-26-000071Section “Summary Compensation Table”. As printed: 2,471,543. Filing ↗machine: r7 · c24 · span 595351–595360
3Section 01, Brian ArchboldDEF 14A2026-07-220000724004-26-000071Section “Summary Compensation Table”. As printed: 2,182,518. Filing ↗machine: r11 · c24 · span 609764–609773
4Section 03, John Sakys PSUDEF 14A2026-07-220000724004-26-000071Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t126 · r6 · c35 · span 663037–663044
5Section 03, Gary Owens PSUDEF 14A2026-07-220000724004-26-000071Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t102 · r1 · c3 · span 496183–496192
6Section 03, Gary Owens RSUDEF 14A2026-07-220000724004-26-000071Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t126 · r3 · c35 · span 647118–647127
7Section 03, Brian Archbold RSUDEF 14A2026-07-220000724004-26-000071Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t126 · r9 · c35 · span 678954–678961
8Section 03, John Sakys RSUDEF 14A2026-07-220000724004-26-000071Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t126 · r6 · c35 · span 663037–663044
9Section 03, Brian Archbold PSUDEF 14A2026-07-220000724004-26-000071Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t102 · r3 · c3 · span 499823–499830
10Section 07, pay ratioDEF 14A2026-07-220000724004-26-000071Section “CEO Pay Ratio”. As printed: 79 : 1. Filing ↗machine: span 1126297–1126299
11Section 08, John SullivanDEF 14A2026-07-220000724004-26-000071Section “Director Compensation”. As printed: 295,000. Filing ↗machine: t65 · r2 · c15 · span 321901–321908
12Section 08, Jennifer AlltoftDEF 14A2026-07-220000724004-26-000071Section “Director Compensation”. As printed: 260,000. Filing ↗machine: t65 · r4 · c15 · span 326684–326691
13Section 08, Tony TripenyDEF 14A2026-07-220000724004-26-000071Section “Director Compensation”. As printed: 260,000. Filing ↗machine: t65 · r7 · c15 · span 333593–333600
14Section 08, Mark CaponeDEF 14A2026-07-220000724004-26-000071Section “Director Compensation”. As printed: 260,000. Filing ↗machine: t65 · r6 · c15 · span 331333–331340
15Section 08, Shiraz LadiwalaDEF 14A2026-07-220000724004-26-000071Section “Director Compensation”. As printed: 260,000. Filing ↗machine: t65 · r3 · c7 · span 323293–323300
16Section 08, Shannon HallDEF 14A2026-07-220000724004-26-000071Section “Director Compensation”. As printed: 250,000. Filing ↗machine: t65 · r5 · c15 · span 328946–328953
17Section 08, Siddhartha KadiaDEF 14A2026-07-220000724004-26-000071Section “Director Compensation”. As printed: 0. Filing ↗
18Section 02, Tony Tripeny 2026-08-13Form 42026-08-170000724004-26-000083Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Siddhartha Kadia 2026-08-13Form 42026-08-170000724004-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, John Sullivan 2026-08-13Form 42026-08-170000724004-26-000085Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Shiraz Ladiwala 2026-08-15Form 42026-08-170000724004-26-000089Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, John Sullivan 2026-08-15Form 42026-08-170000724004-26-000086Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, John Sullivan 2026-08-15Form 42026-08-170000724004-26-000086Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Jennifer Alltoft 2026-08-15Form 42026-08-170000724004-26-000090Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Jennifer Alltoft 2026-08-15Form 42026-08-170000724004-26-000090Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Mark Capone 2026-08-15Form 42026-08-170000724004-26-000091Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Tony Tripeny 2026-08-15Form 42026-08-170000724004-26-000087Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Shannon Hall 2026-08-15Form 42026-08-170000724004-26-000088Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Shiraz Ladiwala 2026-08-15Form 42026-08-170000724004-26-000089Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Mark Capone 2026-08-15Form 42026-08-170000724004-26-000091Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Shannon Hall 2026-08-15Form 42026-08-170000724004-26-000088Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Tony Tripeny 2026-08-15Form 42026-08-170000724004-26-000087Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Tony Tripeny 2026-09-09Form 42026-09-110000724004-26-000092Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Shiraz Ladiwala 2026-09-09Form 42026-09-110000724004-26-000096Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Mark Capone 2026-09-09Form 42026-09-110000724004-26-000097Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Shannon Hall 2026-09-09Form 42026-09-110000724004-26-000094Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, John Sullivan 2026-09-09Form 42026-09-110000724004-26-000093Insider equity transaction reported since the proxy statement. Filing ↗
38Section 06, 2026 voteForm 8-K2026-09-080001437749-26-029813Item 5.07 · say-on-pay result. As reported: 96.93% (votes for as printed: 4,317,389). Filing ↗
39Section 06, 2025 voteForm 8-K2025-08-250001437749-25-027659Item 5.07 · say-on-pay result. As reported: 91.61% (votes for as printed: 4,476,544). Filing ↗
40Section 06, 2024 voteForm 8-K2024-08-300001437749-24-028148Item 5.07 · say-on-pay result. As reported: 94.63%. Filing ↗
41Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
42Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
43Section 09b board cost (computed)Computed——Cash 375,000 + equity 1,210,000 + all other 0 = 1,585,000, summed across the director compensation table rows.machine: formula: Σ = 1,585,000
44Haemonetics Corporation, Section 10b CEO totalDEF 14A2026-06-090000313143-26-000074CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. Filing ↗machine: span 718173–718183
45Sotera Health, LLC, Section 10b CEO totalDEF 14A2026-04-080001104659-26-040937CEO total compensation as printed in Sotera Health, LLC's own proxy. As printed: 10,656,063. Filing ↗machine: span 996859–996869
46Azenta, Inc., Section 10b CEO totalDEF 14A2025-12-180001140361-25-046064CEO total compensation as printed in Azenta, Inc.'s own proxy. As printed: 10,371,414. Filing ↗machine: r2 · c22 · span 1247118–1247129
47Maravai LifeSciences Holdings, Inc., Section 10b CEO totalDEF 14A2026-04-240001823239-26-000014CEO total compensation as printed in Maravai LifeSciences Holdings, Inc.'s own proxy. As printed: 10,129,708. Filing ↗machine: t21 · r3 · c20 · span 502645–502655
48AtriCure, Inc., Section 10b CEO totalDEF 14A2026-04-060001323885-26-000010CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. Filing ↗machine: span 743364–743373
49Neogenomics, Inc., Section 10b CEO totalDEF 14A2026-04-060001077183-26-000014CEO total compensation as printed in Neogenomics, Inc.'s own proxy. As printed: 9,127,092. Filing ↗machine: r2 · c45 · span 869460–869469
50Adaptive Biotechnologies Corporation, Section 10b CEO totalDEF 14A2026-04-240001193125-26-177409CEO total compensation as printed in Adaptive Biotechnologies Corporation's own proxy. As printed: 9,081,690. Filing ↗machine: span 818708–818717
51Standard BioTools, Inc., Section 10b CEO totalDEF 14A2026-04-270001140361-26-017100CEO total compensation as printed in Standard BioTools, Inc.'s own proxy. As printed: 8,823,502. Filing ↗machine: r2 · c22 · span 553256–553266
52Neogen Corporation, Section 10b CEO totalDEF 14A2026-08-210001193125-26-360742CEO total compensation as printed in Neogen Corporation's own proxy. As printed: 8,693,916. Filing ↗machine: span 1672214–1672223
53Veracyte, Inc., Section 10b CEO totalDEF 14A2026-04-220001384101-26-000021CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422
54BioLife Solutions, Inc., Section 10b CEO totalDEF 14A2025-07-080000834365-25-000007CEO total compensation as printed in BioLife Solutions, Inc.'s own proxy. As printed: 7,046,205. Filing ↗machine: span 344908–344917
55Artivion, Inc., Section 10b CEO totalDEF 14A2026-04-010001999371-26-007510CEO total compensation as printed in Artivion, Inc.'s own proxy. As printed: 6,883,108. Filing ↗machine: r3 · c9 · span 741873–741882
56Mesa Laboratories (subject), Section 10b CEO totalDEF 14A2026-07-220000724004-26-000071CEO total compensation as printed in Mesa Laboratories's own proxy. As printed: 6,643,208. Filing ↗machine: r3 · c24 · span 580946–580955
57Quanterix Corporation, Section 10b CEO totalDEF 14A2026-04-240001104659-26-048166CEO total compensation as printed in Quanterix Corporation's own proxy. As printed: 5,250,745. Filing ↗machine: t18 · r1 · c47 · span 503076–503085
58Cytek Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-280001140361-26-017479CEO total compensation as printed in Cytek Biosciences, Inc.'s own proxy. As printed: 5,120,061. Filing ↗machine: r2 · c21 · span 561243–561252
59Pacific Biosciences of California, Inc., Section 10b CEO totalDEF 14A2026-04-230001299130-26-000064CEO total compensation as printed in Pacific Biosciences of California, Inc.'s own proxy. As printed: 4,309,846. Filing ↗machine: r2 · c48 · span 876974–876983
60LeMaitre Vascular, Inc., Section 10b CEO totalDEF 14A2026-04-140001193125-26-153877CEO total compensation as printed in LeMaitre Vascular, Inc.'s own proxy. As printed: 3,780,990. Filing ↗machine: r3 · c18 · span 564038–564047
61Inogen, Inc., Section 10b CEO totalDEF 14A2026-04-280001294133-26-000009CEO total compensation as printed in Inogen, Inc.'s own proxy. As printed: 2,613,804. Filing ↗machine: span 1140571–1140580
62Cryoport, Inc., Section 10b CEO totalDEF 14A2026-04-220001140361-26-016129CEO total compensation as printed in Cryoport, Inc.'s own proxy. As printed: 2,375,524. Filing ↗machine: t277 · r2 · c22 · span 1285130–1285139
63Codexis, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-186994CEO total compensation as printed in Codexis, Inc.'s own proxy. As printed: 2,323,279. Filing ↗machine: r2 · c27 · span 319928–319937
64Section 10a, AtriCure, Inc. reciprocityDEF 14A—0001323885-26-000010AtriCure, Inc.'s most recent proxy was read; its disclosed peer group does not include Mesa Laboratories. Filing ↗
65Section 10a, Azenta, Inc. reciprocityDEF 14A—0001140361-25-046158Azenta, Inc.'s most recent proxy was read; its disclosed peer group does not include Mesa Laboratories. Filing ↗
66Section 10a, Codexis, Inc. reciprocityDEF 14A—0001193125-25-093503Codexis, Inc.'s most recent proxy was read; its disclosed peer group does not include Mesa Laboratories. Filing ↗
67Section 10a, Cytek Biosciences, Inc. reciprocityDEF 14A—0001140361-26-017479Cytek Biosciences, Inc. names Mesa Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗
68Section 10a, Haemonetics Corporation reciprocityDEF 14A—0000313143-26-000074Haemonetics Corporation's most recent proxy was read; its disclosed peer group does not include Mesa Laboratories. Filing ↗
69Section 10a, Inogen, Inc. reciprocityDEF 14A—0001294133-26-000009Inogen, Inc.'s most recent proxy was read; its disclosed peer group does not include Mesa Laboratories. Filing ↗
70Section 10a, LeMaitre Vascular, Inc. reciprocityDEF 14A—0001437749-23-010217LeMaitre Vascular, Inc.'s most recent proxy was read; its disclosed peer group does not include Mesa Laboratories. Filing ↗
71Section 10a, Maravai LifeSciences Holdings, Inc. reciprocityDEF 14A—0001823239-26-000014Maravai LifeSciences Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Mesa Laboratories. Filing ↗
72Section 10a, Neogen Corporation reciprocityDEF 14A—0001193125-26-360742Neogen Corporation's most recent proxy was read; its disclosed peer group does not include Mesa Laboratories. Filing ↗
73Section 10a, Neogenomics, Inc. reciprocityDEF 14A—0001077183-26-000014Neogenomics, Inc.'s most recent proxy was read; its disclosed peer group does not include Mesa Laboratories. Filing ↗
74Section 10a, Quanterix Corporation reciprocityDEF 14A—0001104659-26-048166Quanterix Corporation names Mesa Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗
75Section 10a, Sotera Health, LLC reciprocityDEF 14A—0001104659-26-040937Sotera Health, LLC's most recent proxy was read; its disclosed peer group does not include Mesa Laboratories. Filing ↗
76Section 10a, Veracyte, Inc. reciprocityDEF 14A—0001384101-26-000021Veracyte, Inc.'s most recent proxy was read; its disclosed peer group does not include Mesa Laboratories. Filing ↗
77Section 10a, Standard BioTools, Inc. reciprocityDEF 14A—0001140361-26-017100Standard BioTools, Inc. names Mesa Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗
78Section 10a, Artivion, Inc. reciprocityDEF 14A—0001999371-26-007510Artivion, Inc.'s most recent proxy was read; its disclosed peer group does not include Mesa Laboratories. Filing ↗
79Section 10a, Pacific Biosciences of California, Inc. reciprocityDEF 14A—0001299130-26-000064Pacific Biosciences of California, Inc.'s most recent proxy was read; its disclosed peer group does not include Mesa Laboratories. Filing ↗
80Section 10a, BioLife Solutions, Inc. reciprocityDEF 14A—0000834365-25-000007BioLife Solutions, Inc. names Mesa Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗
81Section 10a, Adaptive Biotechnologies Corporation reciprocityDEF 14A—0001193125-26-177409Adaptive Biotechnologies Corporation names Mesa Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.